Answer
Nov 19, 2025 - 12:07 PM
Leqembi (lecanemab) has been shown to slow the progression of early Alzheimer's disease by about 27% compared to a placebo over 18 months. This translates to a delay of several months in the worsening of symptoms during that period. However, the exact amount of time Leqembi delays Alzheimer's progression can vary for each individual.
